AUTHORS
Hany Elmariah, MD,MS, Shukaib Arslan2, Soyoung Kim, PhD3, Andrew Peterson, MS4, Lori Muffly, MD5, Mark B. Juckett, MD, MHCM6, Michael R. Grunwald, MD7, Tania Jain, MBBS8, Veronika Bachanova, MD, PhD9, Ryan J Stubbins, MD, MSc, FRCPC10, Xia Bi, MD11, Kwang Wooahn, PhD12, Wael Saber, MD13, Betul Oran, MD14, Monzr M. M Al Malki, MD15, Nelli Bejanyan, MD16
AFFILIATIONS
1 Division of Blood and Marrow Transplantation, Stanford University,, Stanford, United States
2 UT Southwestern Medical Center, Dallas, United States
3 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States, Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, United States
4 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States
5 Division of Blood and Marrow Transplantation, Stanford University,, Stanford, United States
6 Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, United States
7 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, United States
8 Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, United States
9 Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, United States
10 Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, Canada, Leukemia/BMT Program of BC, BC Cancer and Vancouver Coastal Health, Vancouver, Vancouver, Canada
11 Thomas Jefferson University Hospital, Inc., Philadelphia, United States
12 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States, Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, United States
13 BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, United States, CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, United States
14 Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, United States
15 City of Hope Cancer Center, Duarte, United States
16 Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, United States
ABSTRACT
Introduction: Reduced intensity conditioning (RIC) haploidentical (haplo) hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) was initially developed with fludarabine/cyclophosphamide/total body irradiation 200 cGy (Flu/Cy/TBI200) conditioning. Multiple alternative RIC regimens are now used, but the optimal RIC platform for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) is unknown.
Methods: We performed a retrospective analysis of patients aged >50 years with AML or MDS who underwent RIC haplo HCT with PTCy-based graft-versus-host disease (GVHD) prophylaxis reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 2015 and 2023. Multivariate (MVA) Cox proportional hazard models were used to compare outcomes among the five most commonly used regimens in the database, adjusting for age, HCT comorbidity index, disease risk, donor/patient sex matching, cytomegalovirus serostatus, and year of transplant. Because of violation of the proportional hazards assumption, we modeled regimens as time-dependent effects, allowing separate effects at < 6 months and > 6 months in models for disease free survival (DFS, primary endpoint), overall survival (OS), transplant related mortality (TRM), and GVHD-free relapse free survival (GRFS) endpoints.
Results: A total of 3015 patients from 162 centers were included with a median follow-up of 50 months (range 3-128). Included regimens were Flu/Cy/TBI200 (reference, n=1867), fludarabine/busulfan +/- TBI (Flu/Bu, n=175), fludarabine/melphalan 100-140 mg/m2 (Flu/Mel, n=122), Flu/Mel+ TBI 200 cGy (Flu/Mel/TBI200, n=468), and Flu/Cy/TBI400 (n=383).
The median age was 66 years (range: 50-82) and was similar across groups. The median HCT-comorbidity index was 3 (range 0-13) with imbalanced distribution across groups (median=2 for Flu/Cy/TBI400 and 3 for all other groups, p < 0.01). Peripheral blood grafts comprised 81%, and the use of marrow grafts was disproportionally high with Flu/Cy/TBI200, Flu/Mel/TBI200, and Flu/Cy/TBI400 (P<0.01). The cohort included 2026 (67%) patients with AML and 989 (33%) patients with MDS, with a similar disease distribution across regimens (p=0.17).
No statistically significant differences in DFS were observed compared to the reference group at either < 6 months or > 6 months in the MVA. OS at < 6 months was inferior with Flu/Bu (HR=1.51, p<0.01), Flu/Mel (HR=2.15, p<0.01), and Flu/Mel/TBI200 (HR=1.50, p<0.01) compared to the Flu/Cy/TBI200 reference group. Pairwise, Flu/Mel resulted in inferior OS compared to Flu/Cy/TBI400 (HR=1.76, p=0.01) at < 6 months. However, no significant differences in OS were observed beyond 6 months.
At < 6 months, TRM was higher across all regimens compared to the reference group: Flu/Bu (HR=1.69, p=0.04), Flu/Mel (HR=3.27, p<0.01), Flu/Mel/TBI200 (HR=2.29, p<0.01), and Flu/Cy/TBI400 (HR=1.50, p<0.01). Pairwise at < 6 months, TRM was higher with Flu/Mel compared to Flu/Bu (HR=1.94, p=0.01), with Flu/Mel compared to Flu/Cy/TBI400 (HR=2.17, p<0.01), and with Flu/Mel/TBI200 compared to Flu/Cy/TBI400 (HR=1.52, p=0.01). At > 6 months, there were no statistically significant differences in TRM between regimens.
Compared to the reference group Flu/Cy/TBI200, relapse was significantly lower at < 6 months with Flu/Mel/TBI200 (HR=0.48, p<0.01) and Flu/Cy/TBI400 (HR=0.51, p<0.01). No differences in relapse were observed > 6 months.
GRFS did not differ significantly from the reference group at either < 6 months or > 6 months. Similarly, there were no statistically significant differences in acute GVHD or chronic GVHD among treatment regimens.
Conclusion: In this large, CIBMTR analysis of RIC haplo HCT with PTCy for AML and MDS, the primary endpoint of DFS was similar across the five evaluated RIC regimens. Traditional Flu/Cy/TBI200 resulted in low TRM and favorable OS in the first 6 months, while Flu/Mel/TBI200 and Flu/Cy/TBI400 yielded lower relapse in the first 6 months. Nonetheless, long-term outcomes beyond 6 months did not differ among regimens. These results suggest the ideal RIC regimen may depend on disease context and patient fitness with Flu/Cy/TBI200 most suitable for less fit patients, while more intensive regimens such as Flu/Mel/TBI200 and Flu/Cy/TBI400 may be considered in fit patients with high risk of relapse.
DISCLOSURES
Hany Elmariah, MD,MS: Orca Bio - Research Funding; BMS - Research Funding; Sanofi - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony)